STATE STREET CORP - CUE BIOPHARMA INC ownership

CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 75 filers reported holding CUE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is 1.21 and the average weighting 0.0%.

Quarter-by-quarter ownership
STATE STREET CORP ownership history of CUE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$1,605,849
-32.4%
698,195
+7.2%
0.00%
Q2 2023$2,377,227
+371.8%
651,295
+361.4%
0.00%
Q1 2023$503,916
-37.4%
141,153
-50.0%
0.00%
Q4 2022$804,572
+155.4%
282,306
+100.0%
0.00%
Q3 2022$315,000
-20.3%
141,153
-11.0%
0.00%
Q2 2022$395,000
-88.9%
158,604
-78.2%
0.00%
Q1 2022$3,548,000
-81.1%
727,023
-56.3%
0.00%
-100.0%
Q4 2021$18,800,000
-1.2%
1,662,252
+27.2%
0.00%0.0%
Q3 2021$19,035,000
+11.1%
1,306,446
-11.1%
0.00%0.0%
Q2 2021$17,126,000
+2.4%
1,470,075
+7.3%
0.00%0.0%
Q1 2021$16,721,000
-4.0%
1,370,605
-1.5%
0.00%0.0%
Q4 2020$17,409,000
-14.5%
1,391,578
+2.8%
0.00%0.0%
Q3 2020$20,367,000
-19.1%
1,353,265
+31.8%
0.00%
-50.0%
Q2 2020$25,169,000
+377.0%
1,026,881
+176.2%
0.00%
Q1 2020$5,276,000
-0.4%
371,783
+11.4%
0.00%
Q4 2019$5,298,000
+119.8%
333,701
+16.7%
0.00%
Q3 2019$2,410,000
-7.1%
285,929
-0.9%
0.00%
Q2 2019$2,593,000
+27.7%
288,386
+9.8%
0.00%
Q1 2019$2,030,000
+57.5%
262,578
-4.3%
0.00%
Q4 2018$1,289,000
-47.0%
274,358
+2.0%
0.00%
Q3 2018$2,432,000
-5.7%
268,981
+23.7%
0.00%
Q2 2018$2,579,000
+55.5%
217,454
+84.3%
0.00%
Q1 2018$1,658,000118,0100.00%
Other shareholders
CUE BIOPHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
Corriente Advisors, LLC 1,915,219$23,959,0005.70%
Prosight Management, LP 906,569$11,341,0005.24%
P.A.W. CAPITAL CORP 140,000$1,751,0001.54%
Voss Capital, LLC 220,714$2,761,0001.39%
Robertson Stephens Wealth Management, LLC 484,000$6,054,0001.26%
Slate Path Capital LP 1,483,619$18,560,0001.00%
Nantahala Capital Management 2,506,772$31,360,0000.97%
PRECEPT MANAGEMENT LLC 150,000$1,877,0000.76%
SANDERS MORRIS HARRIS LLC 193,591$2,449,0000.56%
Rock Creek Group, LP 100,014$1,251,0000.51%
View complete list of CUE BIOPHARMA INC shareholders